Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and molecular features of primary gliosarcoma with digital spatial whole-transcriptome analysis of glial and mesenchymal components.

Brain pathology (Zurich, Switzerland)·2026
Same author

Genomic and Molecular Associations with Preoperative Immune Checkpoint Inhibition in Patients with Stage III Clear Cell Renal Cell Carcinoma.

Cancers·2026
Same author

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway.

bioRxiv : the preprint server for biology·2025
Same author

Genomic and molecular associations with preoperative immune checkpoint inhibition in patients with stage III clear cell renal cell carcinoma.

medRxiv : the preprint server for health sciences·2025
Same author

Novel Genetic Risk Variants Associated with Oral Tongue Squamous Cell Carcinoma.

Head and neck pathology·2025
Same author

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial.

British journal of cancer·2025

Related Experiment Video

Updated: May 11, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Gastrointestinal stromal tumour.

Heikki Joensuu1, Peter Hohenberger, Christopher L Corless

  • 1Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. heikki.joensuu@hus.fi

Lancet (London, England)
|April 30, 2013
PubMed
Summary

Gastrointestinal stromal tumors (GISTs) are rare cancers. Understanding their genetic mutations and treatment options like imatinib is key for improving patient outcomes.

Area of Science:

  • Gastrointestinal Oncology
  • Molecular Pathology
  • Surgical Oncology

Background:

  • Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms originating in the GI tract, primarily the stomach and small intestine.
  • These tumors present with variable malignant potential, often causing symptoms like bleeding, anemia, and pain.
  • GISTs typically express KIT or PDGFRA, with specific kinase-activating mutations driving their development.

Purpose of the Study:

  • To summarize the key characteristics of GISTs, including their origin, clinical presentation, and histopathological markers.
  • To review the genetic landscape of GISTs, focusing on mutations in KIT, PDGFRA, and other relevant genes.
  • To outline current treatment strategies, including surgical resection, adjuvant imatinib therapy, and management of advanced disease with tyrosine kinase inhibitors.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Related Experiment Videos

Last Updated: May 11, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Main Methods:

  • Literature review of GIST epidemiology, pathology, and molecular genetics.
  • Analysis of diagnostic markers, including KIT and anoctamin 1 immunohistochemistry.
  • Review of treatment guidelines and clinical trial outcomes for adjuvant and advanced GIST therapy.

Main Results:

  • GISTs are characterized by mutations in KIT or PDGFRA, with alternative genetic alterations identified in a subset of tumors.
  • Surgery is curative for approximately 60% of patients.
  • Adjuvant imatinib therapy is recommended for high-risk GISTs with sensitive mutations, while tyrosine kinase inhibitors improve survival in advanced disease, despite common secondary resistance.

Conclusions:

  • GISTs are a distinct group of mesenchymal neoplasms with specific molecular drivers.
  • Effective management relies on accurate diagnosis, risk stratification, and targeted therapies.
  • Ongoing research is crucial to overcome treatment resistance and improve long-term survival for advanced GIST patients.